LoopCAR-T1

**LoopCAR-T1** is a novel loop-structured chimeric antigen receptor (CAR) T-cell therapy targeting both **CD19** and **CD22** antigens, designed to address antigen escape and relapse in B-cell malignancies. Developed through systematic functional screening of dual-target constructs (including TanCAR-T1, TanCAR-T2, LoopCAR-T2), it demonstrated superior cytotoxicity, cytokine secretion, and proliferative capacity, leading to its selection for clinical evaluation. In an investigator-initiated, open-label, multicenter trial (Dec 2024–Jun 2025) at Lu Daopei Hospital led by Wei Zhang, MD, LoopCAR-T1 was administered to 18 patients with relapsed/refractory B-NHL (primarily DLBCL, stage III/IV) post-lymphodepleting chemotherapy, achieving an **83% best overall response rate** (67% CR, 17% PR), including 83% response (all CR) in 6 CNS-involved cases. Safety was favorable with 67% CRS (1 grade 3, resolved), **no ICANS** (even in CNS patients), and no CAR-T-related deaths; pharmacokinetics showed median Tmax 14 days, Cmax 91,850 copies/μg DNA.[1][2]